A Retrospective Cohort Study of Extended Dupilumab Dosing in Atopic Dermatitis: Assessing the Impact on Disease Severity and Understanding Characteristics Linked to Successful Dose Extension.

Jessica McClatchy, Vanessa Tran, Gayle Ross

Abstract read

In one paragraph

Article in The Australasian journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jessica McClatchyDermatology Department, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.ORCID https://orcid.org/0009-0008-7139-3493

Vanessa TranDermatology Department, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.

Gayle RossDermatology Department, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0001-5750-1920

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dupilumab is effective for moderate-to-severe atopic dermatitis, but optimal long-term dosing is unclear. In this single-centre retrospective study, 49 patients underwent dose extension to 300 mg Q3W or 300 mg Q4W, with EASI scores remaining low and stable over 18 months. Patients extending for good disease control had higher EASI90 rates. The impact of age, disease severity and therapy duration remains uncertain.

Indexed as

Antibodies, Monoclonal, HumanizedDermatitis, AtopicDermatologic AgentsAdolescentAdultFemaleHumansMaleMiddle AgedRetrospective StudiesSeverity of Illness IndexYoung AdultAntibodies, Monoclonal, HumanizedDermatologic Agentsdupilumab

Identifiers

PMID42324216

DOI10.1111/ajd.70165

PMCPMC13456174

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.